Stroke Thrombectomy Shows Lasting Benefit at One Year in TESLA Trial
Extended TESLA trial data reveals endovascular therapy significantly improves functional outcomes at 1 year for large-core stroke patients.
Summary
The TESLA trial originally showed no clear short-term benefit of mechanical thrombectomy for large-core strokes identified on basic CT scans. But extended follow-up data published in JAMA tells a different story: at one year, patients who received endovascular therapy (EVT) were more than three times as likely to regain functional independence compared to those on medical management alone (23.6% vs 6.8%). The trial is notable for using only standard CT imaging, making it more accessible than trials requiring advanced imaging. Researchers believe the growing gap between groups reflects ongoing neuroplastic recovery in treated patients versus continued decline in untreated ones, offering hope that early reperfusion enables prolonged brain healing well beyond the acute phase.
Detailed Summary
Stroke remains one of the leading causes of long-term disability and death worldwide, making advances in acute treatment directly relevant to healthspan and quality of life. The TESLA trial now adds important long-term evidence supporting mechanical thrombectomy — a procedure that physically removes blood clots — for patients with large-core strokes, a group historically considered poor candidates for intervention.
The original 90-day results from TESLA were neutral, meaning no statistically significant benefit was detected for endovascular therapy (EVT) over standard medical management. However, extended follow-up to one year changed the picture dramatically. Patients treated with EVT showed significantly better functional outcomes, with mean utility-weighted modified Rankin Scale scores of 3.65 versus 2.78 for medical management alone — a clinically meaningful difference confirmed with a posterior probability of superiority of 99.9%.
Functional independence rates told an equally compelling story: 23.6% of EVT patients achieved independence at one year versus just 6.8% in the medical management group. Independent walking was also substantially higher — 35.4% versus 18.0%. Importantly, functional independence in the medical management group actually declined between 90 days and one year, likely reflecting the progressive natural deterioration of untreated large-core brain tissue.
TESLA stands out because it required only standard noncontrast CT imaging for patient selection, unlike other trials using advanced perfusion imaging. This pragmatic approach extends the potential reach of EVT to hospitals without specialized imaging infrastructure. The enrollment window stretched to 24 hours from symptom onset, broader than most comparable trials, with a median 11.5-hour delay to randomization.
These findings align with results from the SELECT2 and TENSION trials and suggest that early reperfusion may trigger prolonged neuroplastic brain remodeling lasting up to a year post-stroke. Clinicians and patients should note these are exploratory extended analyses, and the open-label design introduces potential bias. Still, the convergence of evidence is strengthening the case for EVT in large-core strokes.
Key Findings
- EVT patients were 3.5x more likely to achieve functional independence at 1 year vs medical management alone (23.6% vs 6.8%).
- Independent walking at 1 year was nearly double in EVT patients (35.4% vs 18.0%) compared to medical management.
- Medical management patients declined in function between 90 days and 1 year, suggesting progressive untreated tissue decay.
- TESLA used only standard CT imaging, making findings applicable to hospitals lacking advanced perfusion imaging tools.
- Extended follow-up to 1 year reversed the trial's earlier neutral finding, highlighting the importance of long-term stroke data.
Methodology
This is a news report summarizing a research letter published in JAMA, based on extended follow-up data from the TESLA randomized controlled trial conducted across 47 U.S. stroke centers with 302 patients. MedPage Today is a credible, peer-reviewed-aligned medical news source; the underlying data comes from a named RCT with Bayesian statistical analysis.
Study Limitations
The 1-year analysis is described as exploratory, and the open-label trial design may introduce performance or assessment bias. Baseline imbalances such as age and unmeasured differences in rehabilitation intensity could partly explain outcome divergence. The article is a summary of a research letter; full data tables and subgroup analyses require review of the primary JAMA publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: